Management Team

Management et Operations

bt_bb_section_bottom_section_coverage_image

Chief Executive Officer, Chairman of the BoardIgnacio Faus, Ph.D., MBA

Dr. Ignacio Faus joined NFL Biosciences in 2019 as an investor, then the management team in early 2021 as a director and CEO of NFL Biosciences. In February 2023 he was appointed Chairman of the Board of Directors. Dr. Ignacio Faus has 27 years' experience in large and medium-sized pharmaceutical companies, as well as in private and listed biotech companies: Bristol Myers Squibb, Grupo Uriach, Ferrer and co-founder in 2006 and Managing Director of Palau Pharma (sold in 2013). In recent years, Ignacio Faus has also been a director of several private and listed biotech companies and private equity funds in Europe and the United States. Ignacio holds a PhD in Biochemistry (Indiana University, USA) and an MBA in Entrepreneurship and Finance from the Kellogg School of Management (Northwestern University, USA).

Co-Founder and Chief Operating OfficerBruno Lafont, M.Sc., Executive MBA

Bruno Lafont co-founded NFL Biosciences in 2009, and is in charge of the structuring and technical development of NFL Biosciences and its various projects. Previously, Bruno spent 12 years on the management team of PCM, an international French industrial group, as Innovation Director from 1999 to 2004, then as President and in charge of setting up the group's US subsidiary in Houston (Texas) from 2004 to 2009. Bruno holds an engineering degree in biochemistry from the Institut National des Sciences Appliquées (INSA) in Toulouse, a Master's degree in management from EMLyon, and an Executive MBA from the Ecole Polytechnique Fédérale de Lausanne and HEC Lausanne.

Chief Financial OfficerGuillaume Audema

Guillaume Audema joined NFL Biosciences' Finance Department at the beginning of 2022. Guillaume spent 7 years with the international firms KPMG and then PWC, working on audit and advisory assignments in the organizational and financial fields for companies of all sizes, notably listed on the French and American financial markets. Before joining the team, he spent 3 years on a financial structuring assignment for an SME. Guillaume holds a Master's degree in Accounting and Controlling from the University of Montpellier and a Diplôme Supérieur de Comptabilité et de Gestion.

Senior Clinical Project LeaderMarie-Laure Fraisse

Marie Laure Fraisse joined NFL Biosciences in 2021. After working as a nurse in a number of hospitals for 4 years, Marie-Laure moved into the monitoring and management of clinical studies. Marie-Laure was a Clinical Research Associate (CRA) at Servier Laboratories and then at the Hôpital Régional d'Annecy, before joining Merck Sereno as Clinical Project Manager and Director. She then worked for Théa and Medincell laboratories. Marie-Laure Fraisse holds a nursing diploma and a master's degree in drug development from EudiPharm in Lyon.

Head of Development and ManufacturingLara Babich

Lara joined NFL Biosciences in 2024. She worked as formulation and process scientist for vaccine development at Janssen Infectious Diseases and Vaccines in the Netherlands. In 2018 she joined the Australian biotech Noxopharm, where she was responsible for the CMC development, manufacturing and clinical supply for several international clinical trials. Lara is graduating in industrial biotechnology at the University of Padova in Italy, and she obtained a doctorate in biochemistry from the University of Amsterdam in 2013.

Director of Medical OperationsViolaine Desort-Hénin

Violaine Desort-Henin holds a State Veterinary Doctorate from the University of Lyon, supplemented by university degrees in management of toxicology studies, interpretation of clinical studies, training as an investigator of clinical studies, in product safety and pharmacovigilance, and practical training at the Croix Rousse hospital, at the Cochin hospital, at the APHP and at the Clinique du Parc in Lyon. Violaine has been working for more than 10 years in the preclinical and clinical development of drugs for human use. She was notably in charge of piloting clinical studies within Thea laboratories and the start-ups Eyevensys, iDD Biotech and Adocia.